How should naltrexone be initiated, dosed, and monitored in an adult without active opioid use, severe liver disease, or pregnancy who has a behavioral addiction such as gambling or internet gaming?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Naltrexone for Behavioral Addiction: Initiation, Dosing, and Monitoring

Naltrexone 50 mg once daily is the recommended dose for behavioral addictions such as gambling disorder, based on the strongest available evidence from randomized controlled trials showing significant reductions in gambling urges and behavior. 1, 2

Evidence Base and FDA Status

Naltrexone is not FDA-approved for behavioral addictions—its approved indications are alcohol use disorder and opioid use disorder only. 3 However, multiple double-blind, placebo-controlled trials demonstrate efficacy specifically for pathological gambling disorder, with network meta-analysis confirming naltrexone as one of only two medications (along with nalmefene) with supportive evidence for gambling disorder treatment. 4

Pre-Treatment Assessment

Before initiating naltrexone, verify the following:

  • Confirm opioid-free status: The patient must not be using any opioids, including tramadol, as naltrexone will precipitate severe withdrawal. 3 A minimum 7–10 day opioid-free interval is required for short-acting opioids; patients transitioning from buprenorphine or methadone may require up to 2 weeks. 3

  • Baseline liver function tests: Obtain AST, ALT, bilirubin, and alkaline phosphatase before starting treatment. 5 Naltrexone can cause hepatocellular injury, particularly at doses exceeding 50 mg. 5

  • Screen for active liver disease: While older guidelines contraindicated naltrexone in alcoholic liver disease 6, recent evidence indicates naltrexone is safe even in severe alcohol-associated cirrhosis. 7 However, adequate studies in severe hepatic impairment have not been conducted. 3

  • Pregnancy status: Naltrexone is contraindicated in pregnancy. 8

  • Assess for concurrent alcohol use disorder: Two case series patients with comorbid alcohol use disorder relapsed during naltrexone treatment for gambling. 9 This warrants closer monitoring but is not a contraindication.

Dosing Protocol

Standard Initiation

Start with 25 mg once daily for 3–7 days, then increase to 50 mg once daily. 3, 1 This graduated approach minimizes nausea, which occurs in approximately 47% of patients during the first week. 10

The 50 mg daily dose has been validated in multiple controlled trials for gambling disorder and is equally effective as higher doses (100 mg and 150 mg daily). 1 One open-label study used flexible dosing up to 250 mg daily (mean effective dose 157 mg/day) 10, but the double-blind trial found no additional benefit from doses above 50 mg. 1

Alternative Dosing for Specific Situations

  • Targeted (as-needed) dosing: For gambling disorder specifically, one pilot study instructed patients to take 50 mg naltrexone before gambling or when experiencing craving, rather than daily. 11 This approach may suit patients with episodic gambling patterns, though it requires further validation.

  • Hepatic impairment: In moderate to severe hepatic impairment, do not exceed 50 mg daily (or 1 tablet daily of combination formulations). 12

  • Renal impairment: In moderate to severe renal impairment, reduce the dose by half. 12 Avoid in end-stage renal disease. 12

Expected Timeline of Response

The majority of patients who respond to naltrexone do so by the end of week 4. 10 In controlled trials for gambling disorder:

  • Significant reductions in gambling urges occurred within the first few weeks 1, 2
  • 75% of naltrexone-treated patients were "much or very much improved" by study end (11–18 weeks) compared to 24% on placebo 2
  • One UK case series reported 60% complete abstinence from gambling during treatment, with an additional 20% reducing gambling to minimal levels 9

If there is no meaningful reduction in gambling behavior or urges by 12 weeks, discontinue naltrexone. 5 This 12-week decision point is consistent with FDA guidance for naltrexone-bupropion in obesity (a related indication). 12

Monitoring Requirements

Liver Function Monitoring

Obtain liver function tests every 3–6 months during treatment. 5 Naltrexone undergoes extensive first-pass metabolism (>98%) and can cause hepatocellular injury. 3 In one gambling disorder trial, elevated liver enzymes occurred in four subjects taking concurrent analgesics. 2

Clinical Monitoring

Assess the following at each follow-up visit:

  • Gambling urges and behavior: Use validated instruments such as the Pathological Gambling Adaptation of the Yale-Brown Obsessive Compulsive Scale (PG-YBOCS) or Gambling Symptom Assessment Scale (G-SAS). 1, 2 Trials show significant reductions in both urge and behavior subscales. 1

  • Functional outcomes: Quality of life improves significantly with naltrexone treatment for gambling disorder. 1 One emergency department study of naltrexone for alcohol use disorder showed increased healthy days and decreased depressive symptoms. 13

  • Concurrent substance use: Monitor for alcohol or other substance use, as naltrexone does not affect cocaine or non-opioid drugs of abuse. 3

Common Side Effects

Counsel patients about expected adverse effects:

  • Nausea (47% in first week) 10—can be minimized by starting at 25 mg and slower titration
  • Gastrointestinal symptoms: loss of appetite, abdominal pain 9
  • Neurological symptoms: headaches, dizziness, sedation, vivid dreams 9

These side effects are generally mild and transient. 2 Serious adverse effects are uncommon. 3

Critical Contraindications and Precautions

Absolute Contraindications

  • Current opioid use or anticipated need for opioid analgesia: Naltrexone completely blocks opioid effects and will precipitate withdrawal in opioid-dependent patients. 3 For procedures requiring opioid analgesia (e.g., endoscopy with fentanyl), discontinue naltrexone in advance. 12

  • Acute opioid withdrawal: Do not initiate naltrexone until withdrawal is complete. 3

  • Pregnancy: Naltrexone is contraindicated. 8

Relative Contraindications and Cautions

  • Acute hepatitis or acute-on-chronic liver failure: Safety is unknown in these conditions, though naltrexone's benefit in reducing alcohol consumption may outweigh risks in alcohol-related liver disease. 7

  • Concurrent analgesic use: Elevated liver enzymes occurred in patients taking naltrexone with concurrent analgesics. 2 Monitor liver function closely if this combination is necessary.

  • Seizure disorders: While this is a concern for the bupropion component of naltrexone-bupropion combinations 12, it is not a contraindication for naltrexone monotherapy.

Adjunctive Psychosocial Treatment

Naltrexone must be combined with psychosocial interventions to achieve optimal outcomes. 3 The FDA label explicitly states that naltrexone is effective only when given as part of a comprehensive management plan. 3

For gambling disorder specifically:

  • Cognitive behavioral therapy (CBT) and motivational interviewing have demonstrated efficacy 14
  • Naltrexone trials that showed efficacy included concurrent psychosocial support 1, 2
  • Compliance-enhancing techniques should be implemented for all treatment components 3

Treatment Duration

Continue naltrexone for at least 12 weeks to assess response, with consideration for longer-term treatment (up to 12 months) based on clinical response. 5, 3 The FDA-approved trials for alcohol use disorder used 12-week protocols 3, but clinical practice often extends treatment duration. 5 For gambling disorder, one case series followed patients for variable periods with sustained benefit. 9

Unlike methadone or buprenorphine for opioid use disorder, naltrexone does not reinforce medication compliance and requires external support structures to maintain adherence. 3

Special Populations

Gender Considerations

Men and women respond equally well to naltrexone for gambling disorder. 1 One trial specifically analyzed sex differences and found no significant difference in treatment response. 1

Concurrent Psychiatric Conditions

Most gambling disorder trials excluded patients with significant psychiatric disorders or antidepressant use 12, limiting evidence in this population. However, the multicenter safety study of naltrexone for alcohol use disorder included patients with comorbid psychiatric conditions and found a similar side effect profile. 3

Internet Gaming Disorder

No specific evidence exists for naltrexone in internet gaming disorder. The mechanism of action (opioid receptor antagonism reducing reward pathway activation) 3 suggests potential benefit, but this remains investigational. The gambling disorder evidence provides the closest available proxy for behavioral addictions generally. 14

References

5
Guideline

Naltrexone Dosing and Clinical Guidance

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

8
Guideline

prevention and control of seasonal influenza with vaccines.

MMWR Recommendations and Reports, 2016

10
Research

An open naltrexone treatment study in pathological gambling disorder.

International clinical psychopharmacology, 2001

13
Research

Emergency department-initiated oral naltrexone for patients with moderate to severe alcohol use disorder: A pilot feasibility study.

Academic emergency medicine : official journal of the Society for Academic Emergency Medicine, 2025

Related Questions

Is it safe to use high-dose oral naltrexone together with Vivitrol (extended‑release naltrexone)?
What is the appropriate oral naltrexone dosing schedule for an adult patient?
How long must a patient abstain from alcohol before starting oral naltrexone?
What alcohol consumption thresholds (e.g., standard drinks per day or week) define a patient as a suitable candidate for naltrexone therapy?
After the first oral naltrexone dose, how soon can injectable naltrexone (Vivitrol) be started?
Can a patient with an iodine allergy safely undergo a radioiodine thyroid uptake scan?
What are the differences between wide local excision and breast-conserving surgery (lumpectomy with radiotherapy) for breast tumors?
How should vitamin K1 be administered to a newborn who missed the initial dose and is being treated several days after birth?
With occlusion of the left mid‑distal peroneal artery, loss of flow in the left anterior tibial artery, suspected right anterior tibial artery occlusion and right mid‑distal peroneal artery occlusion causing new right foot weakness, should the patient be taken to the emergency department immediately?
How do I prescribe Megestrol acetate (Megace) oral suspension for an adult cancer patient with appetite loss, including dose, quantity, and refill instructions?
What is the maximum recommended dose of fluvoxamine for treating obsessive‑compulsive disorder in adults?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.